CytoSorbents vs Senseonics
CytoSorbents reported revenue of $37 million in fiscal 2025, about the same as Senseonics' $35 million in fiscal 2025. CytoSorbents' revenue grew 4.1% in its latest year, and Senseonics' grew 56.9%. CytoSorbents had an operating margin of -39.8%, against -193.8% at Senseonics. Free cash flow was −$13 million at CytoSorbents and −$60 million at Senseonics.
Side by side
| CytoSorbents | Senseonics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $37M | $35M |
| Revenue growth | 4.1% | 56.9% |
| Revenue growth a year, last 5 years | −2.0% | 48.4% |
| Gross margin | 71.5% | 44.7% |
| Operating margin | −39.8% | −193.8% |
| Net margin | −22.1% | −196.0% |
| Free cash flow | −$13M | −$60M |
| Free cash flow margin | −33.8% | −170.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 14.3% | 32.5% |
| Last close | $5.13 | $8.90 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $269,332, sold $0 | bought $627,302, sold $0 |
| Piotroski F-score | — | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CytoSorbentsSenseonics
Operating margin
Percent of revenue
CytoSorbentsSenseonics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CytoSorbentsSenseonics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CytoSorbents and Senseonics pages.